United Therapeutics Corporation Financing Cash Flow
United Therapeutics Corporation (UTHR) reported Financing Cash Flow of -$1.36 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- United Therapeutics Corporation net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $122.40M.
- United Therapeutics Corporation net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$1.48B.
- United Therapeutics Corporation net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $98.40M.
- United Therapeutics Corporation net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$956.00M.
- United Therapeutics Corporation net cash provided by (used in) financing activities for fiscal 2025 was -$1.15B.
- United Therapeutics Corporation net cash provided by (used in) financing activities for fiscal 2024 was -$1.25B.
- United Therapeutics Corporation net cash provided by (used in) financing activities for fiscal 2023 was -$11.90M, a 115.78% decline from fiscal 2022.
- United Therapeutics Corporation net cash provided by (used in) financing activities for fiscal 2022 was $75.40M, a 68.30% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $122.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.36B 10-Q · filed 2026-08-05 | -$1.26B derived: sum of 3 quarters · filed 2026-08-05 | -$2.22B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$1.48B 10-Q · filed 2026-05-06 | -$1.39B derived: sum of 2 quarters · filed 2026-05-06 | -$2.34B derived: sum of 3 quarters · filed 2026-05-06 | -$2.54B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $98.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$857.60M derived: sum of 2 quarters · filed 2026-02-25 | -$1.06B derived: sum of 3 quarters · filed 2026-08-05 | -$1.15B 10-K · filed 2026-02-25 |
| 2025-09-30 | -$956.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$1.15B derived: sum of 2 quarters · filed 2026-08-05 | -$1.25B 10-Q · filed 2025-10-29 | -$1.32B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$198.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$292.40M 10-Q · filed 2026-08-05 | -$367.10M derived: sum of 3 quarters · filed 2026-08-05 | -$431.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$93.80M 10-Q · filed 2026-05-06 | -$168.50M derived: sum of 2 quarters · filed 2026-05-06 | -$232.60M derived: sum of 3 quarters · filed 2026-05-06 | -$280.60M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$74.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$138.80M derived: sum of 2 quarters · filed 2026-02-25 | -$186.80M derived: sum of 3 quarters · filed 2026-02-25 | -$1.25B 10-K · filed 2026-02-25 |
| 2024-09-30 | -$64.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$112.10M derived: sum of 2 quarters · filed 2025-10-29 | -$1.18B 10-Q · filed 2025-10-29 | -$1.27B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$48.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | -$1.12B 10-Q · filed 2025-07-30 | -$1.21B derived: sum of 3 quarters · filed 2026-02-25 | -$1.20B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$1.07B 10-Q · filed 2025-04-30 | -$1.16B derived: sum of 2 quarters · filed 2026-02-25 | -$1.15B derived: sum of 3 quarters · filed 2026-02-25 | -$1.13B derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$92.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$85.20M derived: sum of 2 quarters · filed 2026-02-25 | -$60.50M derived: sum of 3 quarters · filed 2026-02-25 | -$11.90M 10-K · filed 2026-02-25 |
| 2023-09-30 | $7.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $32.30M derived: sum of 2 quarters · filed 2024-10-30 | $80.90M 10-Q · filed 2024-10-30 | $136.40M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $24.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $73.30M 10-Q · filed 2024-07-31 | $128.80M derived: sum of 3 quarters · filed 2025-02-26 | $135.80M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $48.60M 10-Q · filed 2024-05-01 | $104.10M derived: sum of 2 quarters · filed 2025-02-26 | $111.10M derived: sum of 3 quarters · filed 2025-02-26 | $135.00M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $55.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $62.50M derived: sum of 2 quarters · filed 2025-02-26 | $86.40M derived: sum of 3 quarters · filed 2025-02-26 | $75.40M 10-K · filed 2025-02-26 |
| 2022-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $30.90M derived: sum of 2 quarters · filed 2023-11-01 | $19.90M 10-Q · filed 2023-11-01 | $27.40M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $23.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $12.90M 10-Q · filed 2023-08-02 | $20.40M derived: sum of 3 quarters · filed 2024-02-21 | $37.00M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | -$11.00M 10-Q · filed 2023-05-03 | -$3.50M derived: sum of 2 quarters · filed 2024-02-21 | $13.10M derived: sum of 3 quarters · filed 2024-02-21 | $23.70M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $7.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $24.10M derived: sum of 2 quarters · filed 2024-02-21 | $34.70M derived: sum of 3 quarters · filed 2024-02-21 | $44.80M 10-K · filed 2024-02-21 |
| 2021-09-30 | $16.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $27.20M derived: sum of 2 quarters · filed 2022-11-02 | $37.30M 10-Q · filed 2022-11-02 | $43.40M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $10.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $20.70M 10-Q · filed 2022-08-03 | $26.80M derived: sum of 3 quarters · filed 2023-02-22 | $32.40M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $10.10M 10-Q · filed 2022-05-04 | $16.20M derived: sum of 2 quarters · filed 2023-02-22 | $21.80M derived: sum of 3 quarters · filed 2023-02-22 | $43.40M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $6.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $11.70M derived: sum of 2 quarters · filed 2023-02-22 | $33.30M derived: sum of 3 quarters · filed 2023-02-22 | -$16.90M 10-K · filed 2023-02-22 |
| 2020-09-30 | $5.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $27.20M derived: sum of 2 quarters · filed 2021-11-03 | -$23.00M 10-Q · filed 2021-11-03 | -$173.00M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $21.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$28.60M 10-Q · filed 2021-08-04 | -$178.60M derived: sum of 3 quarters · filed 2022-02-24 | -$226.90M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$50.20M 10-Q · filed 2021-05-05 | -$200.20M derived: sum of 2 quarters · filed 2022-02-24 | -$248.50M derived: sum of 3 quarters · filed 2022-02-24 | -$248.10M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$150.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$198.30M derived: sum of 2 quarters · filed 2022-02-24 | -$197.90M derived: sum of 3 quarters · filed 2022-02-24 | $611.20M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$48.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | -$47.90M derived: sum of 2 quarters · filed 2020-10-28 | $761.20M 10-Q · filed 2020-10-28 | $761.30M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $809.50M 10-Q · filed 2020-07-29 | $809.60M derived: sum of 3 quarters · filed 2021-02-24 | $812.00M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $809.10M 10-Q · filed 2020-04-29 | $809.20M derived: sum of 2 quarters · filed 2021-02-24 | $811.60M derived: sum of 3 quarters · filed 2021-02-24 | $804.80M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $2.50M derived: sum of 2 quarters · filed 2021-02-24 | -$4.30M derived: sum of 3 quarters · filed 2021-02-24 | $6.30M 10-K · filed 2021-02-24 |
| 2018-09-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | -$4.40M derived: sum of 2 quarters · filed 2019-10-30 | $6.20M 10-Q · filed 2019-10-30 | $8.00M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | -$6.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $3.80M 10-Q · filed 2019-07-31 | $5.60M derived: sum of 3 quarters · filed 2020-02-26 | $9.10M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $10.60M 10-Q · filed 2019-05-01 | $12.40M derived: sum of 2 quarters · filed 2020-02-26 | $15.90M derived: sum of 3 quarters · filed 2020-02-26 | $19.50M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $5.30M derived: sum of 2 quarters · filed 2020-02-26 | $8.90M derived: sum of 3 quarters · filed 2020-02-26 | $43.30M 10-K · filed 2020-02-26 |
| 2017-09-30 | $3.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $7.10M derived: sum of 2 quarters · filed 2018-10-31 | $41.50M 10-Q · filed 2018-10-31 | -$60.20M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $38.00M 10-Q · filed 2018-08-01 | -$63.70M derived: sum of 3 quarters · filed 2019-02-27 | -$196.00M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $34.40M 10-Q · filed 2018-05-02 | -$67.30M derived: sum of 2 quarters · filed 2019-02-27 | -$199.60M derived: sum of 3 quarters · filed 2019-02-27 | |
| 2016-12-31 | -$101.70M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$234.00M derived: sum of 2 quarters · filed 2019-02-27 | -$497.70M 10-K · filed 2019-02-27 | |
| 2016-09-30 | -$132.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-25 | -$396.00M 10-Q · filed 2017-10-25 | ||
| 2016-06-30 | -$263.70M 10-Q · filed 2017-07-27 | |||
| 2015-12-31 | -$447.00M 10-K · filed 2018-02-21 | |||
| 2012-12-31 | -$49.99M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$84.94M derived: sum of 2 quarters · filed 2013-02-26 | -$171.27M derived: sum of 3 quarters · filed 2013-02-26 | -$169.14M 10-K · filed 2013-02-26 |
| 2012-09-30 | -$34.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | -$121.28M derived: sum of 2 quarters · filed 2012-11-01 | -$119.15M 10-Q · filed 2012-11-01 | -$367.67M derived: sum of 4 quarters · filed 2013-02-26 |
| 2012-06-30 | -$86.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | -$84.20M 10-Q · filed 2012-07-26 | -$332.71M derived: sum of 3 quarters · filed 2013-02-26 | -$332.29M derived: sum of 4 quarters · filed 2013-02-26 |
| 2012-03-31 | $2.13M 10-Q · filed 2012-04-26 | -$246.38M derived: sum of 2 quarters · filed 2013-02-26 | -$245.96M derived: sum of 3 quarters · filed 2013-02-26 | -$233.90M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-12-31 | -$248.51M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$248.09M derived: sum of 2 quarters · filed 2013-02-26 | -$236.03M derived: sum of 3 quarters · filed 2013-02-26 | -$218.08M 10-K · filed 2013-02-26 |
| 2011-09-30 | $421.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $12.48M derived: sum of 2 quarters · filed 2012-11-01 | $30.43M 10-Q · filed 2012-11-01 | $94.04M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | $12.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $30.01M 10-Q · filed 2012-07-26 | $93.62M derived: sum of 3 quarters · filed 2013-02-26 | $105.81M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $17.95M 10-Q · filed 2012-04-26 | $81.56M derived: sum of 2 quarters · filed 2013-02-26 | $93.75M derived: sum of 3 quarters · filed 2013-02-26 | $117.62M derived: sum of 4 quarters · filed 2013-02-26 |
| 2010-12-31 | $63.60M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $75.80M derived: sum of 2 quarters · filed 2013-02-26 | $99.67M derived: sum of 3 quarters · filed 2013-02-26 | $146.76M 10-K · filed 2013-02-26 |
| 2010-09-30 | $12.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $36.06M derived: sum of 2 quarters · filed 2011-10-27 | $83.15M 10-Q · filed 2011-10-27 | $93.88M derived: sum of 4 quarters · filed 2012-02-28 |
| 2010-06-30 | $23.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $70.95M 10-Q · filed 2011-07-28 | $81.69M derived: sum of 3 quarters · filed 2012-02-28 | $99.73M derived: sum of 4 quarters · filed 2012-02-28 |
| 2010-03-31 | $47.09M 10-Q · filed 2011-04-28 | $57.82M derived: sum of 2 quarters · filed 2012-02-28 | $75.86M derived: sum of 3 quarters · filed 2012-02-28 | |
| 2009-12-31 | $10.73M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $28.77M derived: sum of 2 quarters · filed 2012-02-28 | $36.48M 10-K · filed 2012-02-28 | |
| 2009-09-30 | $18.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $25.75M 10-Q · filed 2010-10-28 | ||
| 2009-06-30 | $7.70M 10-Q · filed 2010-07-28 | |||
| 2008-12-31 | $213.03M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |